BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

11369

507747

TTKHLTCARE

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

TTK HEALTHCARE LIMITED performance

Today’s low

Today’s high

₹ 1187.20 ₹ 1227.00
₹ 1191.40

52 week low

52 week high

₹ 1101.05 ₹ 1893.95
₹ 1191.40

Open Price

₹ 1216.50

Prev. Close

₹ 1212.10

Volume (Shares)

4077.00

Total traded value

₹ 48.57

Upper Circuit

₹ 1454.50

Lower Circuit

₹ 969.70

info

TTK HEALTHCARE LIMITED Share Price Update

As of the latest trading session, TTK HEALTHCARE LIMITED share price is currently at ₹ 1191.2, which is down by ₹ -20.90 from its previous closing. Today, the stock has fluctuated between ₹ 1187.20 and ₹ 1227.00. Over the past year, TTK HEALTHCARE LIMITED has achieved a return of -21.79 %. In the last month alone, the return has been 2.54 %. Read More...

TTK HEALTHCARE LIMITED fundamentals


  • Market cap (Cr)

    1,683.50

  • P/E Ratio (TTM)

    20.07

  • Beta

    0.62

  • Book Value / share

    732.01

  • Return on equity

    6.46%

  • EPS (TTM)

    48.51

  • Dividend yield

    0.84%

  • Net profit/quarter (Cr)

    16.73

info icon alternate text
  • Market cap (Cr)

    1,681.60

  • P/E Ratio (TTM)

    20.07

  • Beta

    0.57

  • Book Value / share

    732.01

  • Return on equity

    6.46%

  • EPS (TTM)

    48.51

  • Dividend yield

    0.84%

  • Net profit/quarter (Cr)

    16.73

info icon alternate text

TTK HEALTHCARE LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 204.74
Operating Expense 199.98
Net Profit 16.73
Net Profit Margin (%) 8.17
Earnings Per Share (EPS) 11.84
EBITDA 25.52
Effective Tax Rate (%) 25.94
Particulars SEP 2024 (Values in Cr)
Revenue 198.49
Operating Expense 193.00
Net Profit 17.20
Net Profit Margin (%) 8.66
Earnings Per Share (EPS) 12.17
EBITDA 25.93
Effective Tax Rate (%) 25.83
Particulars JUN 2024 (Values in Cr)
Revenue 207.90
Operating Expense 203.91
Net Profit 31.58
Net Profit Margin (%) 15.18
Earnings Per Share (EPS) 22.35
EBITDA 43.69
Effective Tax Rate (%) 22.60
Particulars MAR 2024 (Values in Cr)
Revenue 181.06
Operating Expense 172.89
Net Profit 18.27
Net Profit Margin (%) 10.09
Earnings Per Share (EPS) 12.93
EBITDA 28.48
Effective Tax Rate (%) 24.55
Particulars DEC 2023 (Values in Cr)
Revenue 183.85
Operating Expense 182.04
Net Profit 12.89
Net Profit Margin (%) 7.01
Earnings Per Share (EPS) 9.13
EBITDA 21.24
Effective Tax Rate (%) 27.17
Particulars MAR 2024 (Values in Cr)
Revenue 752.79
Operating Expense 731.29
Net Profit 62.84
Net Profit Margin (%) 8.34
Earnings Per Share (EPS) 44.47
EBITDA 99.94
Effective Tax Rate (%) 25.29
Particulars MAR 2023 (Values in Cr)
Revenue 725.11
Operating Expense 711.81
Net Profit 639.71
Net Profit Margin (%) 88.22
Earnings Per Share (EPS) 452.72
EBITDA 79.69
Effective Tax Rate (%) 27.53
Particulars MAR 2022 (Values in Cr)
Revenue 599.24
Operating Expense 593.23
Net Profit 41.59
Net Profit Margin (%) 6.94
Earnings Per Share (EPS) 29.43
EBITDA 40.66
Effective Tax Rate (%) 25.48
Particulars MAR 2021 (Values in Cr)
Revenue 476.06
Operating Expense 471.46
Net Profit 46.44
Net Profit Margin (%) 9.75
Earnings Per Share (EPS) 32.87
EBITDA 37.35
Effective Tax Rate (%) -62.59
Particulars MAR 2020 (Values in Cr)
Revenue 645.77
Operating Expense 635.12
Net Profit 12.32
Net Profit Margin (%) 1.90
Earnings Per Share (EPS) 8.72
EBITDA 37.07
Effective Tax Rate (%) 36.61
Particulars MAR 2024 (Values in Cr)
Book Value / Share 705.23
ROE % 6.46
ROCE % 8.67
Total Debt to Total Equity 0.03
EBITDA Margin 13.28
Particulars MAR 2023 (Values in Cr)
Book Value / Share 671.59
ROE % 100.43
ROCE % 10.04
Total Debt to Total Equity 0.04
EBITDA Margin 11.01
Particulars MAR 2022 (Values in Cr)
Book Value / Share 230.16
ROE % 12.84
ROCE % 7.60
Total Debt to Total Equity 0.07
EBITDA Margin 6.37
Particulars MAR 2021 (Values in Cr)
Book Value / Share 205.40
ROE % 15.07
ROCE % 5.42
Total Debt to Total Equity 0.09
EBITDA Margin 6.17
Particulars MAR 2020 (Values in Cr)
Book Value / Share 173.09
ROE % 5.01
ROCE % 8.02
Total Debt to Total Equity 0.12
EBITDA Margin 5.74
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 774.94
Total Assets 1200.59
Total Liabilities 1200.59
Total Equity 1000.91
Share Outstanding 14130333
Price to Book Ratio 2.10
Return on Assets (%) 5.23
Return on Capital (%) 6.15
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 847.16
Total Assets 1170.11
Total Liabilities 1170.11
Total Equity 953.38
Share Outstanding 14130333
Price to Book Ratio 1.54
Return on Assets (%) 54.67
Return on Capital (%) 65.35
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 273.50
Total Assets 558.54
Total Liabilities 558.54
Total Equity 329.63
Share Outstanding 14130333
Price to Book Ratio 3.60
Return on Assets (%) 7.44
Return on Capital (%) 11.88
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 227.69
Total Assets 494.27
Total Liabilities 494.27
Total Equity 294.64
Share Outstanding 14130333
Price to Book Ratio 2.41
Return on Assets (%) 9.39
Return on Capital (%) 14.87
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 132.05
Total Assets 431.20
Total Liabilities 431.20
Total Equity 248.99
Share Outstanding 14130333
Price to Book Ratio 1.89
Return on Assets (%) 2.85
Return on Capital (%) 4.45
Particulars MAR 2024 (Values in Cr)
Net Income 84.12
Cash from Operations 20.01
Cash from Investing 28.49
Cash from Financing -21.91
Net change in Cash 1.63
Free Cash Flow 30.39
Particulars MAR 2023 (Values in Cr)
Net Income 838.07
Cash from Operations -8.91
Cash from Investing 31.69
Cash from Financing -12.42
Net change in Cash -5.54
Free Cash Flow 2.78
Particulars MAR 2022 (Values in Cr)
Net Income 57.77
Cash from Operations 54.17
Cash from Investing -29.55
Cash from Financing -10.12
Net change in Cash 5.30
Free Cash Flow 59.68
Particulars MAR 2021 (Values in Cr)
Net Income 37.05
Cash from Operations 76.10
Cash from Investing -77.23
Cash from Financing -17.15
Net change in Cash 2.02
Free Cash Flow 77.83
Particulars MAR 2020 (Values in Cr)
Net Income 19.42
Cash from Operations 30.62
Cash from Investing -13.29
Cash from Financing -10.16
Net change in Cash -3.62
Free Cash Flow 42.86
Company Name Price P/E P/B Market Cap 52 Week Low/High
MAFATLAL INDUSTRIES LTD. 130.00 8.20 0.98 934.84 111.50 / 220.95
ANDREW YULE & COMPANY LTD. 28.11 0.00 3.82 1374.44 22.65 / 65.65
BALMER LAWRIE & CO LTD 200.00 12.93 1.91 3420.08 146.70 / 320.25
BOMBAY CYCLE & MOTOR AGENCY LT 1629.00 22.62 2.22 65.16 1392.10 / 2593.95
THACKER & CO.LTD. 1485.00 7.62 1.11 161.53 635.55 / 2282.85
Company Name Price P/E P/B Market Cap 52 Week Low/High
MAFATLAL INDUSTRIES LTD. 130.00 8.18 0.98 934.84 111.50 / 220.95
EMPIRE INDUSTRIES LTD. 1062.80 14.96 2.08 637.68 823.70 / 1599.00
ANDREW YULE & COMPANY LTD. 28.11 0.00 10.34 1374.44 22.65 / 65.65
BALMER LAWRIE & CO LTD 200.00 16.88 2.48 3420.08 146.70 / 320.25

TTK HEALTHCARE LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1191.40 -1.70 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 1208.70
  • 26 Days 1214.10
  • 10 Days 1216.10
  • 50 Days 1226.90
  • 12 Days 1216.70
  • 100 Days 1286.00
  • 20 Days 1215.10
  • 200 Days 1357.00
1235.70 PIVOT

First Support

1176.40

First Resistance

1271.40

Second Support

1140.70

Second Resistance

1330.70

Third Support

1081.40

Third Resistance

1366.40

RSI

49.23

ADX

54.24

MACD

5.41

Williams % R

-61.56

Commodity Channel Index (CCI)

30.66

Date

2025-04-29

Week

3446.00

Same Day

4139.00

Month

3059.00

1 Year

0.62

3 Year

0.56

Over 1 Month

2.54%

down

Over 1 Year

-21.79%

down

Over 3 Months

-5.20%

down

Over 3 Years

16.57%

down

Over 6 Months

-19.65%

down

Over 5 Years

22.26%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

TTK HEALTHCARE LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
22.4%
Promoter Holdings
74.56%
FII
1.9%
DII
1.13%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
T T Krishnamachari & Co. Represented By Its Partners - Mr T T Jagannathan And Mr T T Raghunathan 9532610.0 (67.46%) Shareholding of Promoter and Promoter Group
Thiruvallur Thattai Jagannathan 759298.0 (5.37%) Shareholding of Promoter and Promoter Group
Jupiter India Fund 215225.0 (1.52%) Public Shareholding
Abakkus Diversified Alpha Fund 159585.0 (1.13%) Public Shareholding
Vidhit Tulshan 146580.0 (1.04%) Public Shareholding
Shanthi Ranganathan 58360.0 (0.41%) Shareholding of Promoter and Promoter Group
Bhanu Raghunathan 56000.0 (0.4%) Shareholding of Promoter and Promoter Group
T T Raghunathan 38797.0 (0.27%) Shareholding of Promoter and Promoter Group
Latha Jagannathan 29728.0 (0.21%) Shareholding of Promoter and Promoter Group
Thiruvallur Thattai Venkatesh 14000.0 (0.1%) Shareholding of Promoter and Promoter Group
Tiruvallur Thatai Lakshman 14096.0 (0.1%) Shareholding of Promoter and Promoter Group
Mukund Thiruvallur Thattai 14096.0 (0.1%) Shareholding of Promoter and Promoter Group
Ttk Tantex Limited 8640.0 (0.06%) Shareholding of Promoter and Promoter Group
Packwell Packaging Products Limited 8775.0 (0.06%) Shareholding of Promoter and Promoter Group
Ttk Prestige Limited 1440.0 (0.01%) Shareholding of Promoter and Promoter Group
Stina Ostlund Vasu 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

TTK HEALTHCARE LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
18 Jul 2023 10.0 Final 18 Jul 2023 Equity shares
26 Jul 2022 10.0 Final 28 Jul 2022 Equity shares
12 Aug 2021 6.0 Final 16 Aug 2021 Equity shares
03 Sep 2020 3.0 Final 07 Sep 2020 Equity shares
01 Aug 2019 5.0 Final 05 Aug 2019 Equity shares
02 Aug 2018 5.0 Final 06 Aug 2018 Equity shares
27 Jul 2017 5.0 Final 31 Jul 2017 Equity shares
28 Jul 2016 5.0 Final 01 Aug 2016 Equity shares
30 Jul 2015 4.5 Final 03 Aug 2015 Equity shares
13 Aug 2014 4.0 Final 19 Aug 2014 Equity shares
16 Jul 2013 4.0 Final 18 Jul 2013 Equity shares
03 Aug 2012 4.0 Final 07 Aug 2012 Equity shares
15 Jul 2011 4.0 Final 19 Jul 2011 Equity shares
16 Jul 2010 3.5 Final 20 Jul 2010 Equity shares
14 Aug 2009 3.0 Final 18 Aug 2009 Equity shares
14 Aug 2008 3.0 Final 19 Aug 2008 Equity shares
14 Aug 2007 2.5 Final 17 Aug 2007 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
18 Jul 2023 10.0 Final 18 Jul 2023 Equity shares
26 Jul 2022 10.0 Final 28 Jul 2022 Equity shares
12 Aug 2021 6.0 Final 16 Aug 2021 Equity shares
03 Sep 2020 3.0 Final 07 Sep 2020 Equity shares
01 Aug 2019 5.0 Final 05 Aug 2019 Equity shares
02 Aug 2018 5.0 Final 06 Aug 2018 Equity shares
27 Jul 2017 5.0 Final 31 Jul 2017 Equity shares
28 Jul 2016 5.0 Final 01 Aug 2016 Equity shares
30 Jul 2015 4.5 Final 03 Aug 2015 Equity shares
13 Aug 2014 4.0 Final 19 Aug 2014 Equity shares
16 Jul 2013 4.0 Final 18 Jul 2013 Equity shares
03 Aug 2012 4.0 Final 07 Aug 2012 Equity shares
15 Jul 2011 4.0 Final 19 Jul 2011 Equity shares
16 Jul 2010 3.5 Final 20 Jul 2010 Equity shares
14 Aug 2009 3.0 Final 18 Aug 2009 Equity shares
14 Aug 2008 3.0 Final 19 Aug 2008 Equity shares
14 Aug 2007 2.5 Final 17 Aug 2007 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

TTK HEALTHCARE LIMITED Share Price

TTK Healthcare Limited, a TTK Group Company was incorporated in May 1958 as Orient Pharma and later renamed as TTK Pharma in Nov '81. The Company is the owner of famous Woodwards Gripewater brand. The Company operate into five main Strategic Business Units namely, Pharmaceuticals, Consumer Products, Medical Devices, Foods and Protective Devices divisions. It is engaged into Animal Welfare Products, Consumer Products, Medical Devices, Protective Devices and Foods Businesses.

In 1992, the company came out with a rights issue at a premium of Rs 35 aggregating Rs 5.81 cr to finance long-term working capital needs, normal capital expenditure, and product promotion.

Products of TTK Healthcare include cardiac care systems, blood management systems, renal care systems, hospital accessories, antibiotics, Woodwards gripe water, animal medicines, etc.

It also has a consumer products and food division manufacturing kiwi shoe polishes, snacks, etc. The company has collaborations with a number of foreign corporations such as London International, Kali-Chemi, Germany; Hatu-ICO, Spain; Nicholas Kiwi, US, etc. The products of the company are exported to the UK, Egypt, the US, Germany, Singapore, Malaysia, Carribean countries, etc.

The Pallavaram plant of the company has been accredited with the ISO 14002 certification by the Bureau of Indian Standards. Also, one of the group companies, TT Maps and Publications was merged with TTK Pharma in 1993.

The company faced some rough weather in Jul.'95 when the MRTPC ordered an inquiry against it for allegedly directing its whole-salers to keep a minimum stock of the company's products and defining their area of operations. During 1996-97, the company has tied up with M/s Mentholatum India Pvt Ltd.

During the year 1999-2000, as a part of the restructuring programme, the paper divison of the company has been disposed off and the merger of TTK Biomed has been approved by the Hon'ble High Court Of Madras with retrospective effect from July 1, 1999.

In 2000-01, the company has vacated the bulk drug business segment by disposing of the Bulk Drugs & Formulations facility at Hyderabad.

The High Court, Madras has approved the scheme of amlagamation between TTK Medical Devices Ltd. and the company.

During the financial year 2003-04,the Heart Valve division of the company has been awarded ISO 9001-2000 Certification by RWTUV,Germany.

Under the Ethical Products Division, Company launched three new products viz., OFORD-LB (Ofloxcacin with Omidazole & Lactobacillus - a broad spectrum antimicrobial); NUROBEST (Methylcobalamin with Alpha Lipoic Acid - to prevent and treat neuropathy); and OSSOPAN-ALFA (Calcium with Alfacalcidol - to prevent and treat Osteoporosis) DURING 2004.

During November 2004, a Strategic Partner was inducted into M/s.TTK Healthcare Services Private Limited, the Subsidiary of Company to infuse further capital into this entity. Consequent to allotment of shares to the said Strategic Partners by TTK Healthcare Services Private Limited, the Shareholding of Company in the said Subsidiary reduced from 56.33% to 35.06% during the year 2004-05 and consequently, TTK Healthcare Services Private Limited ceased to be the Subsidiary of Company.


During 2005, the Company launched OSSOGEMS (Chewable Milk Qalcium) and re-launched ARTHRID (an anti-Arthritis Formulation). Under the Animal Welfare Division, three new products viz., LYSETIK (Deltamethrin), ENROBEST (Enrofloxacin) and TT ZYME (Cocktail Enzyme) have been recently launched. To bring about an enhanced focus on the Herbal'Products Segment, Company launched a New Marketing Division VENTURA. It expanded the Animal Welfare Division operations in Punjab and Uttar Pradesh.

The Company launched Moisturizer under the Brand 'Eva Nourish' during the year 2006. It launched a range of Pain Management Products under the brand name DOLOBEST and three new products viz., CALCITRIOL (a Calcium Supplement), RABULCER-D (an AntiUlcerant) and LEVOCOLD (an Anti-cold preparation) under the Ethical Products Division. It launched 3 new products viz., PROTOGEN-G (Protein Supplement). DELiVERA (Moisturizing Cream) and CLIMACTER (forMenopausal Symptoms) under Ventura Division. It launched quality soap for babies under the brand 'Woodward's Baby Bath' in two variants in Tamil Nadu and Andhra Pradesh under the Consumer Products Division. It launched BLOX (Toxin Binder), TEFROLI FORTE PET (Liver Tonic) and TT-CEF (Cephalosporin Injection) under the Animal Welfare business division.

During the year 2007, the Company launched three new products viz., LYCO-Q (Male Infertility Formulation), ARTHRID OIL (Anti-Arthritis Formulation) and UTRONORM FORTE (Fortified Version of Poly Herbal Uterine Tonic) under the Ventura Division; launched a new product viz., IMMULAR (Herbal Immuno Modulator) under the Animal Welfare Division. It launched a Moisturizer and a Lip Balm under the EVA brand.

During year 2008, the Company launched five new products viz., Lycoprost-SP (for treating prostate enlargement); Dolout-P (pain killer); Krease (pancreatin enzyme); Elcarim IQ (IQ enhancer); and Calzibor (calcium supplement) under the Ventura Division. Animal Welfare Division launched four new products viz., Prophytase (enzyme preparation); Rumibest (digestive powder); Lavitone Liquid & Lavitone-H Injection (vitamin supplement); and Melobest-P (antiinflammatory / analgesic Injection). The business undertaking of Medical Devices Division at Waluj was sold during the year.

During year 2009, the Company launched four formulations viz., LR Zin, LR Zin Forte, CCQ 25 and CCQ 50 into the Ventura Division. Melobest Inj. and Melobest Bolus (Antiinflammatory/Analgesic) were added to the range into the Animal Welfare Division. Fantasy Talc was added to the talcum powder range. Further, EVA Sun Shield got launched under the skin care category. Under the Good Home Range, Room Spray and new variants of Scrubbers such as Large, 2-in-one, Xtra Tough, etc., were introduced into the Consumer Products Division.

In 2010, P-Biotic (a combination of Pre & Probiotic), Urofit (an alkalizer for managing renal stones), Ossopan BMD (a mineral fortified calcium preparation for the treatment of osteoporosis) and Folibest DHA (folic acid and iodine based supplement) were launched into the Ethical Products Division. Company enhanced its presence in the anti-infertility segment with the launch of three new formulations viz., Aromatin (Letrozole), ChromiNac-A (a combination of Chromium Picolinate and N-Acetyl Cysteine) and Carni-Q (a combination of L-Carnitine and Co-enzyme Q10). Increlac (Herbal Galactagogue), Gestaforte Plus Bolus (Fertility Promoter), Blox OA (Toxin Binder with organic acids) were the new products added to the range into the Animal Welfare Division Buisness during the year 2009-10. The Company acquired the Manufacturing Facility for Orthopaedic Implants including Total Knee Replacement System from Invicta Meditek Limited in July 2009 by getting into the Ortho Segment. The Pellet (Pappad) manufacturing line imported from M/s Fen, Italy was erected and commissioned in November, 2010 into the Foods Business. The Lip Balm was introduced into the Consumer Products Division during the year 2010-11.

In November 2012, TTK Protective Devices Limited launched a new brand of Condom 'Skore into the Consumer Products Business division. A small manufacturing facility was set up for manufacturing Instrumentation Sets at Chromepet, Chennai into the Ortho Division. The Fen make Pellet (Pappad) Manufacturing line acquired from M/s McFills, Ahmedabad was commissioned and both the Fen Lines and the old refurbished Pavan Lines started working at full capacity into the Foods Business Division. Thereafter, the Company launched retail packs of Ready-to-fry Snack Pellets (Pappads) in Andhra Pradesh, during First Quarter of 2013-14.

The Company embarked upon growing projects for Foods Business including the new manufacturing facility set up in Jaipur in 2013-14.
It introduced a number of products in Anti-Ulcerant, Respiratory, Infertility and Gynaecology segments to consolidate into these therapeutic segments of Ethical Products Division (EPD) & Ventura Division during 2015-16.

During the year 2016-17, Company introduced a couple of line extensions under 'Ossopan' brand to strengthen the Calcium Segment.

During the year 2016-17, ompany made an investment of Rs.3.40 lakhs in M/s Renew Wind Power (AP) Private Limited, in connection with purchase of wind power, by way of subscription to the issue of 3,400 Equity Shares of face value of Rs.10 each at a price of Rs.100 per Equity Share. Subsequently, 2,500 Equity Shares were transferred to M/s Renew Wind Power (Karnataka Three) Private Limited at a price of Rs.100 each, thus holding the balance 900 Equity Shares of Rs.10 each (Rs.0.90 lakhs) as on 31st March, 2017.

During year 2017-18, TTK Protective Devices Limited and its Wholly Owned Subsidiary TSL Techno Services Limited was merged with the Company through the Scheme of Amalgamation dated 15th December, 2017, where the Appointed Date of the Scheme was 1st April, 2012. Consequent to the above, the erstwhile TTK Protective Devices Limited became a Division of Company and for operational convenience, which was named as 'Protective Devices Division'. The development and testing of Cementless Hip Implant was commissioned into the Ortho Division during the year 2018-19.

During the year 2019-20, the Company had bifurcated the Ventura Division into- (i) Ventura - Gynaec; and (ii) Ventura - Fertility. Jessica QF (a novel pregnancy supplement), Sensipreg SR (progesterone), Erafos (Fosfomycin) and Pufer (a Haematinic) was newly launched in 2019-20. The packaging of the EVA Deodorant was fully revamped with a two tone colour scheme and also complete change in the graphics of the pack. This new pack was launched in March, 2019. Skore brand was extended with pleasure aids like Orgasmic Gel for women, Vibrating Rings as well as Pheromone Activating Spray for men.

During the year 2020-21, the Company launched products such as Bilbay M (Antihistamine) and Ossopan Active (Immunity booster) into the Respiratory and GP/CP segments, respectively.

During the year 2021-22, the Human Pharma Division (Undertaking) of Company was transferred, as a going concern, on a slump sale basis, for a consideration of Rs.805 crores to M/s BSV Pharma Private Limited (BSV), with effect from 9th May, 2022. Two new products, viz., Chirocyst DS and PCO 360 were launched under Ventura Division during 2021-22. The launch of Sponge Wipes and Ultra-scrubbers widened the portfolio into the Good Home Business division during the year.

During the year 2022-23, Company launched the improved Skore 4.0 version with a new packaging and also added lubricants to the range into Protective Devices Business. It recommenced manufacturing operations at the Virudhunagar facility.

Parent organization TTK
NSE symbol TTKHLTCARE
Founded 1958
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of TTK Healthcare Ltd?

Answer Field

The share price of TTK Healthcare Ltd for NSE is ₹ 1191.2 and for BSE is ₹ 1190.05.

What is the Market Cap of TTK Healthcare Ltd?

Answer Field

The market cap of TTK Healthcare Ltd for NSE is ₹ 16,83.50 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52 Week High and Low of TTK Healthcare Ltd?

Answer Field

The 52 Week High and Low of TTK Healthcare Ltd for NSE is ₹ 1893.95 and ₹ 1101.05 and for BSE is ₹ 1923.00 and ₹ 991.00.

How to Buy TTK Healthcare Ltd share?

Answer Field

You can trade in TTK Healthcare Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for TTK Healthcare Ltd?

Answer Field

The 1 year returns on the stock has been -23.99%.

What is the Current Share Price of TTK Healthcare Ltd?

Answer Field

TTK Healthcare Ltd share price is for NSE ₹ 1191.2 & for BSE ₹ 1190.05 as on Apr 30 2025 03:29 PM.

What is the Market Cap of TTK Healthcare Ltd Share?

Answer Field

The market cap of TTK Healthcare Ltd for NSE ₹ 16,83.50 & for BSE ₹ 0.0 as on Apr 30 2025 03:29 PM.

What is the P/E Ratio of TTK Healthcare Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM the price-to-earnings (PE) ratio for TTK Healthcare Ltd share is 20.07.

What is the PB ratio of TTK Healthcare Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM, the price-to-book (PB) ratio for TTK Healthcare Ltd share is 732.01.

How to Buy TTK Healthcare Ltd Share?

Answer Field

You can trade in TTK Healthcare Ltd shares with Bajaj Broking by opening a demat account.

How to Buy TTK Healthcare Ltd Share on Bajaj Broking App?

Answer Field

To buy TTK Healthcare Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “TTK Healthcare Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|